Posted by Michael Wonder on 03 Oct 2018
FDA approves Seysara (sarecycline) for the treatment of moderate to severe acne
2 October 2018 - To be launched in U.S. by Almirall SA.
Paratek Pharmaceuticals today announced that the U.S. FDA has approved Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Paratek has exclusively licensed U.S. development and commercialisation rights of Seysara for the treatment of acne to Allergan, who has assigned such rights to Almirall SA. Paratek retains development and commercialisation rights in the rest of the world.
Seysara (sarecycline) is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties for the potential treatment of moderate to severe acne in the community setting. Under the parties' agreement, Paratek earned a $12 million milestone payment upon FDA approval and is now entitled to receive tiered royalties at rates ranging from high-single to low double digits on net sales of Seysara.
